NVO vs SNY Stock Comparison: AI Score, Valuation, Performance and Upside
Novo Nordisk and Sanofi are both large-cap European pharma companies with blockbuster assets but in completely different therapeutic areas. Novo Nordisk is the GLP-1 obesity/diabetes juggernaut with almost unlimited near-term demand; Sanofi is the immunology and rare disease specialist whose Dupixent continues compounding toward $20B+ peak revenues. NVO has the larger near-term earnings acceleration; SNY offers a more diversified and potentially more stable growth profile.
Novo Nordisk is the pure-play on the obesity treatment revolution — a historic demand catalyst unmatched in recent pharma history; Sanofi is the diversified European pharma with Dupixent as a predictable compounder and optionality from pipeline and divestitures.
SNY holds the edge across 3 of 5 key metrics in this comparison. SNY has delivered stronger 1-year price return (-5.96% vs -26.60%), though NVO has the better forward P/E setup (1.97x vs 7.84x for SNY). On fundamentals, SNY is growing revenue faster (14.60%), while NVO maintains the higher operating margin (42.54%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for SNY (+26.46%) than for NVO (+8.24%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want maximum exposure to the GLP-1 obesity and diabetes treatment revolution
- believe Novo Nordisk's manufacturing scale-up will unlock pent-up demand for years
- value cardiovascular outcome data as a new indication expanding Wegovy's patient eligibility
- are comfortable with competition from Eli Lilly's tirzepatide as the market expands
- want diversified European pharma exposure with Dupixent as a high-conviction compounder
- value rare disease through Genzyme as a stable, defensible revenue base
- prefer a broader therapeutic portfolio rather than concentration in one drug class
- are looking for a lower-risk European pharma at a more moderate valuation versus NVO
| Metric | NVO | SNY |
|---|---|---|
| AI scorei | 40.8 | 41.3 |
| AI ranki | #1107 | #1057 |
| Latest closei | $43.24 | $42.48 |
| 1M returni | -6.97% | -7.31% |
| 6M returni | +24.28% | +0.53% |
| 1Y returni | -26.60% | -5.96% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NVO | SNY |
|---|---|---|
| 1Y ago | $7.71K (-22.9%) started 2025-09-18 | $9.93K (-0.7%) started 2025-09-18 |
| 5Y ago | $10.96K (+9.6%) started 2021-09-20 | $13.88K (+38.8%) started 2021-09-20 |
| 10Y ago | $30.96K (+209.6%) started 2016-09-19 | $27.1K (+171.0%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | NVO | SNY |
|---|---|---|
| Market capi | $191.03B | $101.79B |
| Trailing P/Ei | 10.73 | 22.96 |
| Forward P/Ei | 1.97 | 7.84 |
| Price/Salesi | 0.58 | 2.08 |
| EV/Revenuei | 0.87 | 2.44 |
| Analyst targeti | $46.80 | $53.72 |
| Target upsidei | +8.24% | +26.46% |
| Metric | NVO | SNY |
|---|---|---|
| Revenue growthi | 2.10% | 14.60% |
| Earnings growthi | -20.60% | -91.20% |
| EPS growthi | -20.60% | -91.20% |
| FCF margini | +11.44% | +12.88% |
| Operating margini | 42.54% | 21.03% |
| Profit margini | 35.35% | 8.09% |
| ROIC proxyi | 59.81% | 5.71% |
| Return on equityi | 59.81% | 5.71% |
| Dividend yieldi | 4.15% | 5.70% |
| Payout ratioi | 44.46% | 128.19% |
| Dividend growth streaki | 7 yrs | 2 yrs |
| Betai | 0.34 | 0.28 |
| Debt/equityi | 63.33 | 33.89 |
| Current ratioi | 0.87 | 0.99 |
| Quick ratioi | 0.64 | 0.49 |
Over the past year, NVO and SNY have moved weakly in the same direction (correlation of 0.18), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | NVO | SNY |
|---|---|---|---|
| 1Y | Growthi | -26.60% | -5.96% |
| CAGRi | -26.61% | -5.97% | |
| Volatilityi | 45.62% | 23.39% | |
| Sharpe ratioi | -0.55 | -0.34 | |
| Sortino ratioi | -0.73 | -0.48 | |
| Max drawdowni | 43.67% | 16.70% | |
| Current drawdowni | 29.04% | 14.34% | |
| Avg drawdowni | 23.32% | 9.27% | |
| Ulcer Indexi | 25.69% | 10.17% | |
| Max daily dropi | 16.43% | 4.51% | |
| Max wkly dropi | 26.95% | 8.45% | |
| 5Y | Growthi | -2.69% | +9.91% |
| CAGRi | -0.55% | +1.91% | |
| Volatilityi | 38.91% | 25.16% | |
| Sharpe ratioi | 0.07 | 0.02 | |
| Sortino ratioi | 0.09 | 0.03 | |
| Max drawdowni | 74.70% | 33.52% | |
| Current drawdowni | 68.13% | 21.20% | |
| Avg drawdowni | 25.47% | 11.23% | |
| Ulcer Indexi | 36.55% | 13.38% | |
| Max daily dropi | 21.83% | 19.13% | |
| Max wkly dropi | 33.45% | 17.14% | |
| 10Y | Growthi | +138.86% | +65.46% |
| CAGRi | +9.10% | +5.17% | |
| Volatilityi | 32.71% | 23.48% | |
| Sharpe ratioi | 0.30 | 0.14 | |
| Sortino ratioi | 0.41 | 0.20 | |
| Max drawdowni | 74.70% | 33.52% | |
| Current drawdowni | 68.13% | 21.20% | |
| Avg drawdowni | 17.40% | 9.54% | |
| Ulcer Indexi | 27.26% | 11.67% | |
| Max daily dropi | 21.83% | 19.13% | |
| Max wkly dropi | 33.45% | 18.16% |
| Category | NVO | SNY |
|---|---|---|
| Company | Novo Nordisk A/S | Sanofi S.A. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Novo Nordisk is a Danish pharmaceutical company and global leader in diabetes and obesity treatment. Its GLP-1 receptor agonist drugs — Ozempic (semaglutide, diabetes), Wegovy (semaglutide, obesity), and Victoza — have transformed the company into one of the most valuable in Europe. The cardiovascular risk reduction data for semaglutide (SELECT trial) has expanded the addressable market beyond glycemic control into cardiology. Manufacturing capacity for GLP-1s is the primary constraint on revenue growth. | Sanofi is a French multinational pharmaceutical company with leading franchises in vaccines (Sanofi Pasteur), immunology (Dupixent — co-developed with Regeneron), rare diseases (Genzyme), and general medicines. Dupixent (dupilumab) is the company's growth engine — a blockbuster immunology drug approved for atopic dermatitis, asthma, COPD, and other Th2-driven diseases. Sanofi is refocusing its pipeline on immunology and oncology while exiting businesses like CHC (consumer healthcare) and Opella. |
| Investor focus | Investors track Wegovy and Ozempic volume and market share versus Eli Lilly's tirzepatide, manufacturing capacity expansion milestones, SELECT cardiovascular label expansion, and pipeline for next-generation GLP-1 combinations. | Investors track Dupixent global net sales and label expansion (multiple new indications in the pipeline), the Genzyme rare disease business's growth, vaccine sales including RSV vaccines, and capital allocation decisions around divestitures and pipeline investment. |
- Dominant GLP-1 franchise with global brand recognition and clinical evidence depth others cannot match
- SELECT cardiovascular outcome data expanded addressable patient population significantly
- 80+ years of diabetes expertise creates a scientific and manufacturing moat in biologics
- Dupixent is one of the fastest-growing large-molecule drugs globally with 10+ indications and expanding
- Genzyme rare disease franchise provides stable, high-margin revenue with limited competition
- Sanofi Pasteur vaccine portfolio including mRNA RSV candidates provides platform diversification
- Manufacturing capacity bottleneck constrains near-term growth even as demand is unlimited
- Eli Lilly's tirzepatide (Mounjaro/Zepbound) is capturing market share with superior efficacy data
- Pricing pressure from potential CMS negotiation and PBM reimbursement changes
- Dupixent is co-developed and co-commercialized with Regeneron — Sanofi books only a portion of profits
- General medicines revenue is declining as older products face generic competition
- Dupixent is available in the US through Regeneron's channel, creating complexity in revenue recognition
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.